|
MechanismTXA2 synthase inhibitors |
|
|
|
Inactive Indication- |
Drug Highest PhaseApproved |
First Approval Ctry. / Loc.JP |
First Approval Date27 Mar 1992 |
100 Clinical Results associated with Nankai Yungong Pharmaceutical Co Ltd
0 Patents (Medical) associated with Nankai Yungong Pharmaceutical Co Ltd
100 Deals associated with Nankai Yungong Pharmaceutical Co Ltd
100 Translational Medicine associated with Nankai Yungong Pharmaceutical Co Ltd